Clinical coverage criteria for GLP-1 / GIP agents (Saxenda, Wegovy, Zepbound) for weight management and Wegovy for MACE risk reduction
Customize your policy alerts
Sign up for all Neighborhood Health Plan of Rhode Island policy alerts
Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical coverage criteria and prior authorization requirements for Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide) for weight reduction and for Wegovy for major adverse cardiovascular event (MACE) risk reduction. Applies to commercial members of Neighborhood Health Plan of Rhode Island.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial Therapy
Authorization of 6 months may be granted when ALL of the following are met:
Continuation Therapy
Authorization of 6 months may be granted when ALL of the following are met:
For the Wegovy indication for reduction of major adverse cardiovascular events (MACE), patients with type 2 diabetes are explicitly excluded. Ozempic (semaglutide) is the indicated agent for MACE risk reduction in adults with type 2 diabetes mellitus and established cardiovascular disease, and the policy directs that Wegovy’s MACE indication only apply to non–type 2 diabetes patients with documented established cardiovascular disease and appropriate guideline-directed medical therapy or a documented clinical reason not to receive it.
Separately, the policy requires that patients who will receive Wegovy for the MACE indication meet the same documentation for established cardiovascular disease and current receipt of guideline-directed medical therapy (or have a documented clinical reason not to receive GDMT) as described for initial and continuation approvals.
The policy prohibits use of the requested medication in combination with any other GLP-1 receptor agonist. Patients must not be concurrently treated with another GLP-1 RA at the time of initial request or during continuation; combination therapy with multiple GLP-1 agents is not permitted.
Continuation authorizations require documentation of medication tolerability and ongoing lifestyle measures. Specifically, clinical notes must document tolerability of the medication and continued adherence to a reduced-calorie diet with increased physical activity. Continuation may be considered not medically necessary if documentation of tolerability, lifestyle participation, or achievement of the policy’s weight‑loss thresholds or other continuation criteria is not provided.
Quantity Limits, Thresholds, and Coding Details
| Saxenda 18mg/3ml | Quantity limit: 5 pens per 30 days |
| Wegovy (various strengths) | Quantity limit: 4 pens per 28 days |
| Zepbound (2.5mg–15mg/0.5ml) | Quantity limit: 4 pens per 28 days |
Prior Authorization, Documentation & Required Actions
Prior authorization: 6‑month approvals; continuation requires documentation
Prior authorization may be granted for an initial 6-month period when initial criteria are met. Continuation authorizations are also for 6 months but require documentation of tolerability, continued reduced‑calorie diet and increased physical activity, completion of the specified trial period and treatment on the FDA‑recommended maintenance dose, and meeting continuation thresholds (e.g., ≥5% weight loss for adult Wegovy/Saxenda/Zepbound) or other continuation criteria described in the policy.
Behavioral program prerequisite: monthly participation ≥6 months
Approval requires prior documentation that the patient has been actively participating in a comprehensive weight management program that includes behavioral health counseling, nutritional/dietary counseling, and physical activity, with meetings at least monthly for at least 6 months before approval.
Required clinical documentation: baseline (and current for continuation) weight/BMI, lifestyle and program notes
Submit baseline weight and BMI and clinical notes documenting active participation in a comprehensive weight management program (behavioral health counseling, nutritional/dietary counseling, and physical activity with monthly meetings ≥6 months). For continuation, provide current weight and BMI and clinical notes documenting tolerability, continued reduced‑calorie diet, increased physical activity, completion of the required trial period and that the patient is on the FDA‑recommended maintenance dose.
- Baseline weight and body mass index (BMI).
- Clinical notes documenting reduced‑calorie diet and increased physical activity.
- Documentation of active participation in a comprehensive weight management program (behavioral and nutritional counseling) with monthly meetings ≥6 months.
- For Wegovy MACE indication, documentation of established cardiovascular disease and current guideline‑directed medical therapy or reason not treated.
Denial risk: missing baseline weight/BMI or behavioral program documentation
Lack of documentation of baseline weight and BMI or of prior participation in a comprehensive weight management program (monthly meetings for ≥6 months) may preclude approval of initial requests.
Definitions and Background
Glucagon‑like peptide‑1 receptor agonists (e.g., liraglutide, semaglutide) and the dual GIP/GLP‑1 agonist tirzepatide are indicated for chronic weight management in adults and, for some agents, in adolescents. These therapies are intended to be used as part of a comprehensive weight management strategy that includes behavioral counseling, nutritional guidance, and increased physical activity. For Wegovy specifically, there is also an evidence‑based indication for reduction of major adverse cardiovascular events in selected patients with established cardiovascular disease when other MACE‑directed therapy considerations are met.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.